Código QR (código de barras bidimensional)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of ROS1-rearranged NSCLC that responded to crizotinib after tumor progression due to MET polysomy during...

ver descrição completa

Na minha lista:
Principais autores: Toshiaki Takakura, MD, Hiroaki Kanemura, MD, MPH, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2023-06-01
coleção:JTO Clinical and Research Reports
Assuntos:
ROS1
MET polysomy
Entrectinib
Crizotinib
Non–small cell lung cancer
Case report
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2666364323000620
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados